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Use of antiviral drugs to 
reduce COVID-19 
transmission 
As the coronavirus disease 2019 
(COVID-19) spreads, efforts are being 
made to reduce transmission via 
standard public health interventions 
based on isolation of cases and tracing 
of contacts. In their modelling study, 
Joel Hellewell and colleagues1 predict 
that such a strategy could contribute to 
reducing the overall size of an outbreak, 
but will still be insufficient to achieve 
outbreak control of COVID-19 when 
the basic reproduction number (R0) is 
higher than 1·5 or the proportion of 
contacts traced is lower than 80%.
One of the main assumptions of the 
model by Hellewell and colleagues is 
that all individuals with symptomatic 
infection with severe acute respiratory 
syndrome (SARS) coronavirus 2 
(SARS-CoV-2) are eventually tested 
and reported. However, under the 
guidelines of most countries with 
low-grade transmission, clinicians will 
test suspected patients only if they 
have travelled to an epidemic region 
since the outbreak began. A second 
assumption of the model is that 
isolation of cases is 100% effective 
in stopping transmission. Yet home 
confinement of infected individuals 
and contacts is challenging, efficacy 
is variable, and the rigorous tracking 
involved requires a considerable 
amount of public health resources. 
The current COVID-19 emergency 
warrants the urgent development of 
potential strategies to protect people 
at high risk of infection—particularly 
close contacts and health-care 
workers, among others—even if more 
robust data on antiviral therapies is 
yet to come. A key reason for such 
an approach is the high estimates for 
the secondary attack rates of SARS-
CoV-2 in households (~15%) and 
among close contacts (~10%).2 Pre-
exposure prophylaxis and post exposure 
prophylaxis (PEP) with antimicrobial 
drugs are effective in preventing illness 
before potential exposure or after 
documented exposure to a variety of 
microbial pathogens, and in reducing 
the risk of secondary spread of infection. 
Based on experiences with PEP for other 
infections, we recommend starting 
PEP as soon as possible after a recent 
possible exposure to SARS-CoV-2. For 
example, PEP with rifampicin is given 
to people exposed to index cases of 
invasive meningococcal infection, and 
oseltamivir has been recommended by 
WHO for people at high risk of infection 
before or after exposure to pandemic 
influenza.3
Antiviral drugs administered shortly 
after symptom onset can reduce 
infectiousness to others by reducing viral 
shedding in the respiratory secretions 
of patients (SARS-CoV-2 viral load in 
sputum peaks at around 5–6 days after 
symptom onset and lasts up to 14 days), 
and targeted prophylactic treatment 
of contacts could reduce their risk of 
becoming infected.3 
The implementation of antiviral 
treatment and prophylaxis has several 
requirements. The stockpile of drugs 
must be adequate, the safety of 
treatment must be very high, and costs 
should ideally be low. The antimalarial 
drug, hydroxychloroquine, is licensed 
for the chemoprophylaxis and 
treatment of malaria and as a disease-
modifying antirheumatic drug. It 
has a history of being safe and well 
tolerated at typical doses. Notably, the 
drug shows antiviral activity in vitro 
against coronaviruses, and specific-
ally, SARS-CoV-2.4 Pharmacological 
model ling based on observed drug 
concentrations and in vitro drug 
testing suggest that prophylaxis with 
hydroxychloroquine at approved doses 
could prevent SARS-CoV-2 infection 
and ameliorate viral shedding.5 
Clinical trials of hydroxychloroquine 
treatment for COVID-19 pneumonia 
are underway in China (NCT04261517 
and NCT04307693). We are reviewing 
the results from China as they emerge. 
The first study (NCT04261517) has 
showed positive preliminary outcomes 
(albeit not conclusive because of the 
small sample size) in terms of clinical 
management, with published data 
expected soon.
We are planning a multicentre 
randomised control led tr ia l 
(NCT04304053) to evaluate the 
efficacy of antiviral treatment 
in anyone found to be infected, 
and the efficacy of prophylactic 
hydroxychloroquine in preventing 
secondary SARS-CoV-2 infections 
and disease symptoms among all 
contacts. Our objective is to evaluate 
the reduction in transmissibility of 
SARS-CoV-2 and in disease progression 
among the contacts of an index case. 
The design intervention is based on 
the design used during the Ebola ça 
Suffit vaccination trial for Ebola in 
2015.6 A person newly diagnosed with 
the disease becomes the index case, 
around whom an epidemiologically 
defined ring of contacts is formed. 
This ring is then randomised to either 
intervention or control in a 1:1 ratio on 
an open-label basis. The study will be 
done over the course of the COVID-19 
outbreak in the Catalonia region of 
Spain, with initial results expected in 
May, 2020. Identifying a treatment 
for the prevention of COVID-19 would 
change the course of the outbreak 
entirely.
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